Jacobs Levy Equity Management
ADCT icon

Jacobs Levy Equity Management’s ADC Therapeutics ADCT Stock Holding History

Jacobs Levy Equity Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151K Buy
+141,344
New +$412K ﹤0.01% 917

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jacobs Levy Equity Management's ADCT Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 141,344 shares worth $151K. The stake represents ﹤0.01% of the portfolio and ranks #917 among its holdings.

114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Jacobs Levy Equity Management held 141,344 shares of ADC Therapeutics worth $151K as of Q2 2026.
  • ADC Therapeutics was a new Jacobs Levy Equity Management position in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #917 holding.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.